Ozurdex implant yields significant visual gain in pseudophakic patients with DME

A steroid-eluting implant improved vision for 3 years in pseudophakic patients with diabetic macular edema, according to an expert.In June, the U.S. Food and Drug Administration approved Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) for adults with DME who are pseudophakic or are phakic and scheduled for cataract surgery.

Full Story →